Announcements
Announcement on behalf of AP Biosciences that preemptive rights forfeited by directors are over 50% and made available to specific persons
1.Date of occurrence of the event:2022/08/08 2.Reason for the forfeiture of subscription rights by the directors nd supervisors: In accordance with related laws and regulations, to coordinate with AP Biosciences’ …
Announcement that the cumulative reduction of shareholding in major subsidiary, AP Biosciences, has reached more than 10%
1.Name of major subsidiary:AP Biosciences, Inc. (hereinafter referred to as “AP Biosciences”) 2.Cause of occurrence (reduce the percentage of shareholding (or capital contribution to) or lose control ):Reduce the percentage …
OBI forfeits subscription of AP Biosciences’ cash capital increase, distributes rights to its shareholders and sets target date
1.Date of occurrence of the event:2022/08/08 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable 5.Cause of occurrence:To be conducted …
The Company’s BOD resolved to forfeit the subscription of AP Biosciences’ cash capital increase and distribute the rights to its shareholders
1.Date of occurrence of the event:2022/08/08 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable 5.Cause of occurrence: In accordance …
OBI’s BOD resolved employees and amount granted for the first issuance of RSU and authorized the decision of record date to the Chairman
1.Date of occurrence of the event:2022/08/08 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable. 5.Cause of occurrence: (1)The Annual …
The Company’s Board of Directors approved the amendment of 2022 Restricted Stock Awards Issuance Rules
1.Date of occurrence of the event:2022/08/08 2.Date of the original announcement and reporting:2022/05/06 3.Summary of the content originally announced and reported: The Board of Directors and the Annual Shareholders’ meeting …
Announcement of the Consolidated Financial Statements for the second quarter of 2022 were approved by the Board of Directors
1.Date of the board of directors submitted or approved:2022/08/08 2.Date of the audit committee approved:2022/08/08 3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):2022/01/01~2022/06/30 …
Announcement on behalf of subsidiary, Obigen Pharma Inc., that BOD resolved the Term Sheet for licensing of OBI-858 in China
1.Date of occurrence of the event:2022/07/21 2.Counterparty to the contract or commitment:A pharmaceutical company in China 3.Relationship with the Company:None 4.Starting and ending dates (or rescission date) of the contract …
SUPPLEMENTARY STATEMENTS ON NEWS ARTICLE
1.Date of occurrence of the event:2022/07/04 2.Company name:OBI Pharma Inc. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:Not applicable 5.Name of the reporting media:2022/7/4 …
The Company announces discontinuation of the Phase II Study of OBI-888
1.Date of occurrence of the event:2022/07/01 2.New drug name or code:Passive Immunotherapeutic Monoclonal Antibody, OBI-888 3.Indication:An immunotherapeutic monoclonal antibody targeting Globo H for the treatment of cancer. Clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/show/NCT03573544 https://www1.cde.org.tw/ct_taiwan/search_case2.php?caseno_ind%5B1%5D=6213 …